CG
RCKT icon

Cutler Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Cutler Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2K Buy
+8,000
New +$227K ﹤0.01% 1890
2021
Q3 		– Sell
-3,800
Closed -$13K – 6239
2021
Q2 		$13K Buy
3,800
+500
+15% +$21.7K ﹤0.01% 3693
2021
Q1 		$4K Buy
3,300
+3,000
+1,000% +$165K ﹤0.01% 4550
2020
Q4 		$5K Buy
+300
New +$10.9K ﹤0.01% 3690
2017
Q1 		– Sell
-2,750
Closed -$3K – 7045
2016
Q4 		$3K Sell
2,750
-6,875
-71% -$196K ﹤0.01% 5373
2016
Q3 		$105K Buy
9,625
+8,750
+1,000% +$275K ﹤0.01% 1764
2016
Q2 		$1K Sell
875
-125
-13% -$4.39K ﹤0.01% 6211
2016
Q1 		$6K Sell
1,000
-2,700
-73% -$81K ﹤0.01% 4679
2015
Q4 		$4K Buy
+3,700
New +$161K ﹤0.01% 5101

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cutler Group's RCKT Position: Q1 2024 in Review

Cutler Group sold out of Rocket Pharmaceuticals (RCKT) in Q1 2024, closing a stake of 100 shares — an estimated $2.84K sold.

Cutler Group first reported a position in RCKT in Q4 2015 and held it in 15 quarters. The position peaked at $414K in Q4 2016. 186 funds tracked by Wall St. Rank hold RCKT as of Q1 2024.

  • Cutler Group reported no remaining Rocket Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 100 Rocket Pharmaceuticals shares in Q1 2024, an estimated $2.84K.
  • Cutler Group first reported a position in Rocket Pharmaceuticals in Q4 2015 and held it in 15 quarters.
  • Cutler Group's Rocket Pharmaceuticals position peaked at $414K in Q4 2016.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.